May 19, 2016
Perspectives on Key Presentations in GI Cancer from ASCO-GI 2022: Part II
Rapid Reactions is a video series that provides commentary from key experts summarizing data released at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) focused on gastric, gastroesophageal, and esophageal cancer. Please join Minsig Choi, MD, from Stonybrook University Cancer Center, as he discusses the following 3 pivotal presentations from ASCO-GI 2022:
- Results of the GERCOR NEONIPIGA phase 2 study indicated that neoadjuvant therapy with nivolumab and ipilimumab was feasible and was associated with a high pathologic complete response rate in patients with microsatellite instability/DNA mismatch repair deficiency resectable esophagogastric junction and gastric adenocarcinoma
- Findings of the phase 2 study of FOLFOX plus nab-paclitaxel indicated that the anthracycline-based triplet regimen was associated with a high response rate and expected toxicities in patients with metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma
- Results of the Ni-HIGH study showed that the combination of nivolumab plus trastuzumab and either S-1 or capecitabine plus oxaliplatin was tolerable and demonstrated promising antitumor activity in chemotherapy-naïve patients with HER2-positive advanced gastric cancer
Read the Articles Discussed in the Video
-
Neoadjuvant Nivolumab plus Ipilimumab and Adjuvant Nivolumab in Patients with Localized Microsatellite Instability-High/Mismatch Repair Deficient Gastric Adenocarcinoma: GERCOR NEONIPIGA
-
FOLFOX plus FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma
-
Nivolumab plus Trastuzumab with S-1/Capecitabine plus Oxaliplatin for HER2-Positive Advanced Gastric Cancer: The Ni-HIGH Study
Related Articles
Rapid Reactions - March 11, 2022
Nivolumab plus Trastuzumab with S-1/Capecitabine plus Oxaliplatin for HER2-Positive Advanced Gastric Cancer: The Ni-HIGH Study
Results of the Ni-HIGH study showed that the combination of nivolumab plus trastuzumab and either S-1 or capecitabine plus oxaliplatin was tolerable and showed promising antitumor activity in chemotherapy-naïve patients with HER2-positive advanced gastric cancer.
Uncategorized - January 5, 2016
Alectinib: an Anaplastic Lymphoma Kinase (ALK) Inhibitor
ALK Rearrangements in Lung AdenocarcinomaALK has been found to fuse with other partners, leading to potent malignant transformation.1,2 The most common among ALK fusion genes in lung cancer, specifically non–small cell lung cancer (NSCLC), is the EML4 ALK translocation fusion gene (EML4-ALK).1,3-5 The relative prevalence of ALK translocation mutations among [ Read More ]
- Neoadjuvant Nivolumab plus Ipilimumab and Adjuvant Nivolumab in Patients with Localized Microsatellite Instability-High/Mismatch Repair Deficient Gastric Adenocarcinoma: GERCOR NEONIPIGA
- FOLFOX plus FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma
- Nivolumab plus Trastuzumab with S-1/Capecitabine plus Oxaliplatin for HER2-Positive Advanced Gastric Cancer: The Ni-HIGH Study
Related Articles
Rapid Reactions - March 11, 2022
Nivolumab plus Trastuzumab with S-1/Capecitabine plus Oxaliplatin for HER2-Positive Advanced Gastric Cancer: The Ni-HIGH Study
Results of the Ni-HIGH study showed that the combination of nivolumab plus trastuzumab and either S-1 or capecitabine plus oxaliplatin was tolerable and showed promising antitumor activity in chemotherapy-naïve patients with HER2-positive advanced gastric cancer.
Uncategorized - January 5, 2016
Alectinib: an Anaplastic Lymphoma Kinase (ALK) Inhibitor
ALK Rearrangements in Lung AdenocarcinomaALK has been found to fuse with other partners, leading to potent malignant transformation.1,2 The most common among ALK fusion genes in lung cancer, specifically non–small cell lung cancer (NSCLC), is the EML4 ALK translocation fusion gene (EML4-ALK).1,3-5 The relative prevalence of ALK translocation mutations among [ Read More ]